The Platform Group AG elevates 2026 forecast after key acquisitions

The Platform Group AG has updated its financial forecasts and recent corporate activities. The revised forecast for the 2026 financial year now projects net sales of approximately €1.0 billion, an increase from the previous forecast of over €860 million. Adjusted EBITDA is also expected to rise to a range of €70 million to €80 million, up from over €64 million previously. Gross merchandise volume (GMV) is anticipated to reach around €1.7 billion, compared to the earlier €1.6 billion. The forecast for the 2025 financial year remains unchanged.

This positive revision is largely attributed to strategic acquisitions, including a majority stake in Apothekia GmbH, a pharmaceutical training platform. The Platform Group AG also holds a 50% interest in the Contracta Group, which fully owns Pharmosan and 79.5% of Vamida.

Further expansion includes additional acquisitions in the "Optics & Hearing" sector in October. The "Service & Retail Goods" segment will be renamed "Pharma & Service Goods" and is expected to grow as a result of these transactions, which are subject to antitrust approval and are expected to close by the end of 2025. Two further agreements in the "Optics & Hearing" segment are expected to generate single-digit million sales with an EBITDA margin of around 24%.